Tenaya Therapeutics (TNYA) Fundamental Analysis: Revenue, Earnings & Valuation

5.19 / 10

Netural

Fundamental rating is neutral (5.2/10). Strengths include cash‑to‑market value, high inventory turnover, solid fixed‑asset turnover and strong YoY revenue growth. Weaknesses are low PB‑ROE, negative asset‑to‑market value, modest revenue‑to‑market, zero tax‑to‑profit ratio and thin gross margin, yielding a balanced view.

Analysis Checks(6/10)

Revenue-MV

Value-0.11

Score1/3

Weight11.82%

1M Return4.95%

Total operating revenue (YoY growth rate %)

Value134.00

Score3/3

Weight3.06%

1M Return1.54%

Inventory turnover ratio

Value103.94

Score3/3

Weight15.68%

1M Return6.74%

Gross profit margin (%)

Value41.83

Score1/3

Weight-1.11%

1M Return-0.63%

PB-ROE

Value-0.32

Score1/3

Weight13.14%

1M Return5.29%

Income tax / Total profit (%)

Value0.00

Score1/3

Weight-0.90%

1M Return-0.50%

Fixed assets turnover ratio

Value9306.28

Score3/3

Weight2.02%

1M Return1.06%

Cost of sales ratio (%)

Value64.41

Score3/3

Weight9.07%

1M Return4.32%

Asset-MV

Value-0.55

Score3/3

Weight33.29%

1M Return11.84%

Cash-MV

Value0.02

Score2/3

Weight13.93%

1M Return5.94%

Is TNYA fundamentally strong?

TNYA scores 5.19/10 on fundamentals and holds a Fair valuation at present. Backed by its -83.84% ROE, 0.00% net margin, -1.66 P/E ratio, 1.22 P/B ratio, and 54.96% earnings growth, these metrics solidify its Netural investment rating.